Decibel Therapeutics's long-term debt is $9.2M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2023), DBTX shows a long-term debt of $9.2M. That compares with $12M in the prior-year period — down 21.7% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, DBTX's long-term debt is now $9.2M (was $12M) — a 21.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Decibel Therapeutics is outperforming or lagging.
Tracking DBTX's long-term debt over time shows whether Decibel Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $9.2M That compares with $12M in the prior-year period — down 21.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Decibel Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $9.2M) with ownership activity and broader fundamentals.
Decibel Therapeutics's long-term debt is $9.2M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.